This is the second specialty pharmacy selected to distribute Tavneos, a first-in-class, oral therapy to treat a group of autoimmune diseases characterized by inflammation and damage to small blood vessels.
PANTHERx Rare Pharmacy has been selected by ChemoCentryx as a limited distribution partner for new drug Tavneos (avacopan). PANTHERx Rare Pharmacy, part of Envolve Pharmacy Solutions, is a growing rare pharmacy licensed in all 50 states, and holds accreditations from URAC, NABP, and ACHC.
The FDA approved Tavneos Oct. 8, 2021. It is the first of its kind orally administered selective complement 5a receptor inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. This is a rare systemic disease in which over-activation of the complement pathway leads to inflammation and destruction of small blood vessels.
The approval was based on phase 3 data of 330 patients with ANCA-associated vasculitis in 20 countries. The study met its primary endpoints of disease remission at 26 weeks and sustained remission at 52 weeks, as assessed by the Birmingham Vasculitis Activity Score.
The most common adverse reactions were: nausea, headache, hypertension, diarrhea, vomiting, rash, fatigue, upper abdominal pain, dizziness, blood creatinine increase, and paresthesia.
ANCA-associated vasculitis is a rare disease with an estimated prevalence of 200 to 400 cases per million people and is more prevalent in middle-age white men and women. The incidence has increased over time, likely due to improvements in diagnosis.
ChemoCentryx has developed TAVNEOS Connect, a patient support program. To learn more visit the website here.